- Next-generation gene editing system has applications in development of cell and gene therapies
- Base editing builds on CRISPR offering and will expand Horizon’s research tools and services
- Horizon seeks partners to assess and shape platform development
Cambridge, UK, 14 January 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation technologies, today announced that it will provide access to a novel base editing technology licensed from Rutgers, The State University of New Jersey, for exclusive use in therapeutic, diagnostic and services applications. This technology is incorporated into Horizon’s next-generation gene editing platform to enable the development of novel therapeutics that rely on engineering patient’s cells either directly in the body (gene therapy), or externally before transplanting back into the patient (cell therapy). This platform will also expand the Company’s research tools and service provisions.
The Company formed an exclusive partnership with Rutgers in January 2019 to further develop the novel base editing technology invented by Dr. Shengkan Jin, associate professor of pharmacology, and co-inventor Dr. Juan C. Collantes, post-doctoral research fellow at Rutgers Robert Wood Johnson Medical School, and has since been funding research in base editing at the University while undertaking its own evaluation and proof-of-concept studies. Horizon has a number of internal programs designed to accelerate the clinical uptake of this technology and is now seeking 3–5 partners to assess and shape the development of its Pin-point™ base editing platform.
Horizon will offer partners access to a novel system that could be used to progress more effective multi-gene knockout cell therapy programs through clinical development with an improved safety profile. Partners will also gain access to the Company’s expertise in genome engineering of different cell types, access to early technical data, and influence over the direction of future development.
Base editing is a novel technology for engineering DNA in cells, which the potential to correct certain errors or mutations in the DNA, or inactivate disease-causing genes. Compared with currently available gene editing methodologies such as conventional CRISPR/Cas9, which creates “cuts” in the gene that can lead to adverse or negative effects, this new technology allows for accurate gene editing while reducing unintended genomic changes that could lead to deleterious effects in patients.
Dr. Jonathan Frampton, Corporate Development Partner, Horizon Discovery, said: “The technology could have a significant impact in enabling cell therapies to be progressed through clinical trials and towards commercialization. Horizon is pleased to offer an effective and precise base editing technology and, alongside Rutgers, aims to make base editing available to all appropriate cell and gene therapy companies as well as research departments. Partnering with leading organizations will help us to drive innovation and deliver the best therapy for the patient.”
Dr. Shengkan 'Victor' Jin of Rutgers University stated: “The cytidine deaminase version of the technology alone could potentially be used for developing cell therapies such as gene modified cells for sickle cell anemia and beta thalassemia, HIV resistant cells for AIDS, over-the-shelf CAR-T cells for cancer, and MHC-compatible allogenic stem cells for transplantation. Other applications could include use as gene therapies for inherited genetic diseases including antitrypsin deficiency and Duchenne muscular dystrophy. In addition, we intend to take full advantage of the unique modularity and versatility features of Pin-point platform and develop efficient gene inactivation agents for potential treatment of many devastating diseases where the leading causal contributing factors are well defined. At the top of this disease list are Alzheimer’s disease, amyotrophic lateral sclerosis, and familial hypercholesterinemia.”
Dr. S. David Kimball, Senior Vice President for Research and Economic Development at Rutgers University, added: “The gene editing technology developed by Rutgers has the potential to revolutionize how scientists think about their search for better options and outcomes in the treatment of disease. It has the potential to solve some of the most persistent global health challenges. This partnership with Horizon Discovery is paving the way to deliver biotherapies for precision medicine and diagnostics and improve human health. I am proud that Rutgers, together with Horizon, is among the frontrunners in the field of gene editing.”
For further information on the Pin-point base editing system, please contact Dr. Jonathan Frampton Corporate Development Partner, Horizon Discovery: firstname.lastname@example.org
Notes to Editors
Dr. Jonathan Frampton, Corporate Development Partner, Horizon Discovery
For a high res image please contact email@example.com
For further information from Horizon Discovery Group plc, please contact:
Zyme Communications (Trade and Regional Media)
Tel: +44 (0)7811 996 942
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5700
About base editing
Many human diseases have a simple and known cause, i.e. a single genetic alteration caused through heredity genetics or by an infectious agent. Examples include genetic diseases such as sickle cell anemia and Duchenne muscular dystrophy, as well as infectious diseases such as AIDS and hepatitis B. Despite the clear and simple cause, a cure is understandably difficult because the approved drugs, as well as most drugs under development, target a disease-associated target or protein rather than impacting the disease-causing gene itself. Equally, while early cell therapies such as CAR-T have been proven to be effective in targeting some types of cancer using a patient’s own T-cells, development of off-the-shelf therapies, or modifications of T-cells to allow targeting of a broader range of cancers, requires significant genetic modification of the cells.
CRISPR gene editing technology allows targeted recognition and modification of specific disease-causing DNA sequences in the genes of cells. However, first generation CRISPR technology generates double-strand DNA breaks and often requires disease tissues or cells to have homologous-dependent repair activity to achieve optimum therapeutic effect. The first generation technology arguably has major hurdles to overcome for developing therapeutic vehicles or agents; in particular for developing in vivo therapeutics the double-stranded DNA breaks generated are potentially harmful to the patient and homologous-dependent repair activity is absent in most disease-affected organs.
The Pin-point base editing system has the potential to overcome the issues above by utilizing a nuclease-deficient CRISPR protein that recruits a non-nuclease DNA modifying enzyme, such as a cytidine deaminase, to the disease-causing gene via an RNA-based recruitment mechanism, where the deamination achieves the desired genotypic effect while minimizing the generation of the potentially oncogenic DNA breaks. This allows accurate editing of genes with an improved safety profile due to minimized unintentional genomic changes.
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") drives the application of gene editing and gene modulation within the global life science market – supporting scientists on the path from research to therapy.
Built upon more than a decade of experience in the engineering of cell lines, Horizon offers an unmatched portfolio of tools and services to help scientists gain a greater understanding of gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.
Horizon’s solutions enable almost any gene to be altered, or its function modulated, in human and other mammalian cell lines. The Company’s customers include many of the world’s foremost academic institutes, global pharmaceutical and biotechnology companies as well as clinical diagnostic laboratories. Insight into the challenges faced by these organizations enables the company to focus efforts on development of innovative solutions that not only differentiate the company’s offering, but also fuel development of the next wave of precision medicines.
Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.
About Rutgers University
Rutgers, The State University of New Jersey, is a leading national research university and the state of New Jersey’s preeminent, comprehensive public institution of higher education. Established in 1766, the university is the eighth oldest higher education institution in the United States. More than 70,000 students and 23,400 full- and part-time faculty and staff learn, work, and serve the public at Rutgers locations across New Jersey and around the world.